[1]刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察*[J].陕西医学杂志,2019,(12):1630-1633.
　LIU Ruili,LIU Xiaohong,LI Huirong,et al.Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis[J].,2019,(12):1630-1633.
点击复制

主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年12期
页码:
1630-1633
栏目:
临床研究
出版日期:
2019-12-05

文章信息/Info

Title:
Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis
文章编号:
DOI:10.3969/j.issn.10007377.2019.12.014
作者:
刘瑞丽1; 刘小红1; 李会荣1; 雷 静2△
1陕西省宝鸡市妇幼保健院妇科（宝鸡 721000）；2陕西省宝鸡市妇幼保健院妇女保健科（宝鸡 721000）
Author(s):
LIU Ruili; LIU Xiaohong; LI Huirong; et al.
Baoji Women's and Children's Health Hospital of Shaanxi Province(Baoji 721000)
关键词:
主动循环腹腔热灌注化疗; 卵巢癌; 腹腔积液; 预后; 血管内皮生长因子
Keywords:
Key words Active circulation intraperitoneal hyperthermic perfusion chemotherapy; Ovarian cancer; Seroperitoneum; Prognosis; Vascular endothelial growth factor
分类号:
R7373
文献标志码:
A
摘要:
摘 要 目的：研究主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液的效果及对患者预后的影响。方法：选择卵巢癌伴腹腔积液患者90例，按随机数表法分为对照组及观察组。对照组采用常规静脉化疗治疗，观察组在对照组基础上采用主动循环腹腔热灌注化疗治疗，两组患者均治疗6个疗程并随访1年。统计两组患者肿瘤及腹腔积液疗效、1年生存率、化疗不良反应发生率，检测并比较治疗前后腹水中血管内皮生长因子（VEGF）、癌抗原（CA125）、人附睾蛋白4（HE4）水平。结果：观察组肿瘤治疗疾病控制率（8222%）高于对照组（6222%）（P＜005）；观察组腹腔积水治疗有效率、疾病控制率（7333%、9556%）均高于对照组（5111%、7778%）（P＜005）；观察组治疗后VEGF、CA125、HE4水平均低于对照组（P＜005）；观察组1年生存率为8667%（39/45）高于对照组6667%（30/45）（P＜005）；两组患者化疗不良反应发生率无统计学差异（P＞005）。结论：主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液可提升治疗效果，并降低肿瘤标志物水平。
Abstract:
Abstract Objective:To study the curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosisMethods:Selection of 90 patients with ovarian cancer and ascitesThey were divided into control group and observation group according to random number table methodThe control group was given routine intravenous chemotherapyOn this basis,observation group was given active circulation intraperitoneal hyperthermic perfusion chemotherapyBoth groups were treated for 6 courses and followed up for 1 yearThe curative effect of tumor and seroperitoneum,1year survival rate,incidence of side effects by chemotherapy in both groups were statistically analyzedThe levels of vascular endothelial growth factor(VEGF),cancer antigen(CA125) and human epididymis protein 4(HE4)in ascites before and after treatment were measuredResults:The disease control rate of tumor treatment in observation group was higher than that in control group(8222% vs 6222%)(P＜005)The response rate of seroperitoneum treatment and disease control rate(7333%,9556%) in observation group were higher than those in control group(5111%,7778%)(P＜005)After treatment,VEGF,CA125 and HE4 levels in observation group were lower than those in control group(P＜005)The 1year survival rate of observation group was higher than that of control group\[8667%(39/45) vs 6667%(30/45)\](P＜005)There was no significant difference in incidence of side effects by chemotherapy between the two groups(P＞005)Conclusion:Active circulation intraperitoneal hyperthermic perfusion chemotherapy in treatment of ovarian cancer combined with seroperitoneum can improve curative effect and reduce levels of tumor markers

参考文献/References:

[1] Coburn SB,Bray F,Sherman ME,et al.International patterns and trends in ovarian cancer incidence,overall and by histologic subtype[J] .International Journal of Cancer,2017,140(11):24512460
[2] Torre LA,Trabert B,Desantis CEOvarian cancer statistics,2018[J] .Histopathology,2018,68(4):284296
[3] 李 霞,于春霞血清肿瘤标志物联合检测在卵巢癌早期诊断中的临床价值研究[J] .临床和实验医学杂志,2016,15(18):17771780
[4] 刘 云,杜 成,刘文超卵巢癌治疗新进展[J] .现代肿瘤医学,2015,23(4):553556
[5] Piso P,Dahlke MH,Loss M,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer[J] .Journal of Surgical Oncology,2017,116(3):21
[6] 卢 锦,王金华卵巢癌的发病机制与分子靶向治疗研究进展[J] .肿瘤研究与临床,2018,30(3):204207
[7] 罗利平,赵富清,刘清秀,等卵巢子宫内膜异位症恶变与卵巢癌患者临床病理特征对比分析[J] .医学临床研究,2018,35(2):278280
[8] 孙佳星,蔡爱露低频超声联合顺铂对卵巢癌细胞影响研究[J] .临床军医杂志,2016,44(12):12461249
[9] 周 敏,张 靖,赵西侠热疗联合紫杉醇对卵巢癌A2780细胞增殖、侵袭及AKT磷酸化的影响[J] .现代肿瘤医学,2015,23(20):29042907
[10] 郭 艳,陈友国晚期上皮性卵巢癌三种腹腔化疗方案的疗效和安全性比较[J] .现代医学,2017,45(3):126128
[11] 张林风,孙文妹,李文娟，等先期化疗联合肿瘤细胞减灭术后腹腔热灌注化疗治疗晚期卵巢癌的临床疗效分析[J] .实用癌症杂志,2016,31(9):14951497
[12] 刘贤莲,杨 蕾细胞减灭术辅助术后腹腔热灌注化疗联合静脉化疗对卵巢癌患者血清恶性生物学指标的影响[J] .海南医学院学报,2015,21(10):14111414
[13] 王宝娜,杨 阳,苏佩佩,等主动循环与单灌单抽腹腔热灌注化疗治疗卵巢癌腹腔积液的对比研究[J] .肿瘤,2017,37(10):8489
[14] 李成浩,李 鹏恒温热循环腹腔灌注化疗对卵巢癌伴腹腔积液患者相关肿瘤标志物及预后影响[J] .临床军医杂志,2017,45(8):848850
[15] 张彩霞,杨有莲高精度持续循环腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的安全性和有效性分析[J] .癌症进展,2018,16(14):17861789

相似文献/References:

[1]高 燕,杨 红,刘淑娟,等.线粒体动态蛋白在卵巢癌中的表达及临床意义[J].陕西医学杂志,2021,50(12):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
　GAO Yan,YANG Hong,LIU Shujuan,et al.Expression and clinical significance of mitochondrial dynamic protein of 51 kDa in ovarian cancer[J].,2021,50(12):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
[2]段小霞,郭 华,付 婷,等.震颤同系物-5过表达对卵巢癌细胞A2780增殖和凋亡的影响[J].陕西医学杂志,2022,51(5):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
　DUAN Xiaoxia,GUO Hua,FU Ting,et al.Effect of quaking homolog-5 overexpression on proliferation and apoptosis of ovarian cancer cell line A2780[J].,2022,51(12):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
[3]耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
　GENG Haihui,CAO Aihua.Expression levels of various serum tumor markers in ovarian cancer patients and their diagnostic value for the disease[J].,2022,51(12):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
[4]王 静,张虹宇,张 磊,等.动脉灌注分数联合转化生长因子-β及上皮细胞钙黏蛋白检测对原发性卵巢癌的诊断价值研究[J].陕西医学杂志,2023,52(7):858.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.019]
[5]王 静,张虹宇,张 磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,(2):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein[J].,2024,(12):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
[6]刘玉锋,薛芳芳.卵巢癌患者造血前B细胞白血病转录因子相互作用蛋白表达和术前中性粒细胞与淋巴细胞比值水平及其临床检测价值[J].陕西医学杂志,2024,(5):662.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.019]
[7]冷小飞,张逸群,魏 峰,等.长链非编码RNA RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及作用机制实验研究[J].陕西医学杂志,2024,(8):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
　LENG Xiaofei,ZHANG Yiqun,WEI Feng,et al.Effect of long non-coding RNA RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its mechanism[J].,2024,(12):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
[8]司 晗,李洁妹,宗佳琪,等.高糖环境对卵巢癌细胞侵袭和迁移的影响及其机制实验研究[J].陕西医学杂志,2024,(8):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
　SI Han,LI Jiemei,ZONG Jiaqi,et al.Effect of high glucose environment on the invasion and migration of ovarian cancer cells and its mechanism[J].,2024,(12):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
[9]王 静,张虹宇,张 磊,等.长链非编码RNA PVT1调控表皮生长因子受体/有丝分裂原活性蛋白激酶通路对卵巢癌细胞的影响实验研究[J].陕西医学杂志,2024,(11):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Effect of long non-coding RNA PVT1 on ovarian cancer cells by regulating epidermal growth factor receptor/mitogen-activated protein kinase pathway[J].,2024,(12):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
[10]周佳敏,赵诗杰,朱小兰,等.RNA甲基化修饰在卵巢癌中的作用研究进展[J].陕西医学杂志,2024,(11):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]
　ZHOU Jiamin,ZHAO Shijie,ZHU Xiaolan,et al.Research progress on the role of RNA methylation modifications in ovarian cancer[J].,2024,(12):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]

备注/Memo

备注/Memo:
*陕西省科学技术研究发展计划项目(2016LMZ16016286)
更新日期/Last Update: 2019-12-19